期刊
BJU INTERNATIONAL
卷 103, 期 4, 页码 441-445出版社
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1464-410X.2008.08280.x
关键词
PSA; PCA3; prostate cancer; biopsy; decision
The decision to take a prostate biopsy is traditionally guided by a digital rectal examination and measurement of serum total prostate-specific antigen (tPSA). However, both techniques are subject to inherent weaknesses. The prostate cancer gene 3 (PCA3), a gene-based marker, specific for prostate cancer, supplements the predictive power of tPSA to improve diagnosis of disease. Including this new marker in the standard of care for men at risk of prostate cancer should be considered, as it presents marked potential for better decision making for a prostate biopsy and for improving overall patient care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据